Human sulfatase-1 inhibits the migration and proliferation of SMMC-7721 hepatocellular carcinoma cells by downregulating the growth factor signaling

Hepatology Research

Volumn 43, Issue 5, 2013, Pages 516-525

  Liu, Hu ^a   Fu, Xiaohui ^a   Ji, Weidan ^a   Liu, Kai ^a   Bao, Longlong ^a   Yan, Yan ^a   Wu, Mengchao ^a   Yang, Jiahe ^a   Su, Changqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Human sulfatase 1; Migration; Proliferation; Signaling pathway

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HUMAN SULFATASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; SHORT HAIRPIN RNA; SULFATASE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR FORMATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84876990543     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01080.x     Document Type: Article

References (38)

1. He J, Gu D, Wu X etal. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-34.
2. Parkin DM. Global cancer statistics in the year. Lancet Oncol 2000; 2001 (2): 533-43.
3. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP Jr. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 2003; 162: 341-51.
4. Lai J, Chien J, Staub J etal. Loss of hSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003; 278: 23107-17.
5. Lai JP, Chien J, Strome SE etal. hSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004; 23: 1439-47.
6. Lai JP, Chien JR, Moser DR etal. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004; 126: 231-48.
7. Narita K, Staub J, Chien J etal. hSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006; 66: 6025-32.
8. Li J, Kleeff J, Abiatari I etal. Enhanced levels of Hsulf-1 interfere with heparin binding growth factor signaling in pancreatic cancer. Mol Cancer 2005; 4: 14-9.
9. Abiatari I, Kleeff J, Li J, Felix K, Büchler MW, Friess H. hSulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol 2006; 59: 1052-8.
10. Dai Y, Yang Y, MacLeod V etal. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 2005; 280: 40066-73.
11. Lai JP, Sandhu DS, Shire AM, Roberts LR. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 2008; 39: 149-58.
12. Ji W, Yang J, Wang D etal. hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS ONE 2011; 6: e23274.
13. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2007; 2: e392.
14. Li J, Mo ML, Chen Z etal. hSulf-1 inhibits cell proliferation and invasion in human gastric cancer. Cancer Sci 2011; 102: 1815-21.
15. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
16. Plotnikov A, Chuderland D, Karamansha Y, Livnah O, Seger R. Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol 2011; 31: 3515-30.
17. Kang YH, Yang IJ, Shin HM. Herbal formula HMC05 prevents human aortic smooth muscle cell migration and proliferation by inhibiting the ERK1/2 MAPK signaling cascade. J Nat Med 2012; 66: 177-84.
18. Song LJ, Liu RJ, Zeng Z etal. Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2, and P-ERK. J Mol Med 2012; 90: 707-18.
19. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006; 66: 11613-22.
20. Cole GW Jr, Alleva AM, Zuo JT etal. Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res 2006; 26: 809-21.
21. Tsubaki M, Satou T, Itoh T etal. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 2012; 259: 402-10.
22. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Jr. Regulation of wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001; 293: 1663-6.
23. Niemann HH. Structural insights into Met receptor activation. Eur J Cell Biol 2011; 90: 972-81.
24. Matsui S, Osada S, Tomita H etal. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol 2010; 37: 289-97.
25. Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012; 32: 190-5.
26. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.
27. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27: 5477-85.
28. Di Cristofano A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27: 5527-41.
29. Ming M, He YY. PTEN in DNA damage repair. Cancer Lett 2012; 319: 125-9. doi:10.1016/j.canlet.2012.01.003.
30. Hu H, Li Z, Chen J etal. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut 2011; 60: 710-21.
31. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011; 16: 485-94.
32. Carrillo de Santa Pau E, Arias FC, Caso Peláez E etal. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009; 115: 1701-12.
33. Vempati P, Mac Gabhann F, Popel AS. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS ONE 2010; 5: e11860.
34. Khurana A, Liu P, Mellone P etal. hSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res 2011; 71: 2152-61.
35. Liu P, Khurana A, Rattan R etal. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res 2009; 69: 4843-50.
36. Staub J, Chien J, Pan Y etal. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 2007; 26: 4969-78.
37. Lai JP, Yu C, Moser CD etal. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 2006; 130: 2130-44.
38. Lai JP, Sandhu DS, Moser CD etal. Additive effect of apicidin and doxorubicin in sulfatase 1-expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol 2009; 50: 1112-21.